FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Cipla Difluprednate Ophthalmic Emulsion Recall

Difluprednate Ophthalmic Emulsion, 0

CIPLA · Warren, NJ

Risk level
Class II
Reported by FDA
Sep 14, 2022
Recall ID
D-1499-2022
Check your lot numberHow we source this data

Summary

Cipla recalled Difluprednate Ophthalmic Emulsion starting Aug 22, 2022. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-1499-2022 on Sep 14, 2022. Reason: Lack of Assurance of Sterility: customer complaint for defective container where breakage of the protective cap exposes tip of eye drop which could compromise sterility. Status: Terminated.

Why it was recalled

Lack of Assurance of Sterility: customer complaint for defective container where breakage of the protective cap exposes tip of eye drop which could compromise sterility.

Product description

Difluprednate Ophthalmic Emulsion, 0.05%, 5 mL bottle, RX only, Manufactured by Cipla Ltd., India, Manufactured for: Cipla USA, Inc., NJ 07059, NDC 69097-341-35.

Lot numbers, UPCs & expiration codes

Lot #: DEG1HC2, DEG2HC2, DEG3HC2, DEG4HC2, DEG5HC2, DEG6HC2, Exp 01/2023; DEG1IC2, DEG2IC2, DEG3IC2, DEG4IC2, Exp 02/2023; DEG1LC2, DEG2LC2, Exp 05/2023; DEG1BD2, DEG2BD2, DEG3BD2, Exp 07/2023

Where it was sold

Nationwide in the USA

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-1499-2022
Classification
Class II
Status
Terminated
Recall initiated
Aug 22, 2022
FDA report date
Sep 14, 2022
Quantity
117,844 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
CIPLA

Original FDA data

Every field from FDA enforcement report D-1499-2022, exactly as published.

Show all FDA fields
City
Warren
State
NJ
Status
Terminated
Country
United States
Event ID
90796
Address
10 Independence Blvd
Code information
Lot #: DEG1HC2, DEG2HC2, DEG3HC2, DEG4HC2, DEG5HC2, DEG6HC2, Exp 01/2023; DEG1IC2, DEG2IC2, DEG3IC2, DEG4IC2, Exp 02/2023; DEG1LC2, DEG2LC2, Exp 05/2023; DEG1BD2, DEG2BD2, DEG3BD2, Exp 07/2023
Postal code
07059-2730
Report date
Sep 14, 2022
Product type
Drugs
Recall number
D-1499-2022
Classification
Class II
Recalling firm
CIPLA
Product quantity
117,844 bottles
Termination date
Nov 27, 2023
Reason for recall
Lack of Assurance of Sterility: customer complaint for defective container where breakage of the protective cap exposes tip of eye drop which could compromise sterility.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Difluprednate Ophthalmic Emulsion, 0.05%, 5 mL bottle, RX only, Manufactured by Cipla Ltd., India, Manufactured for: Cipla USA, Inc., NJ 07059, NDC 69097-341-35.
Distribution pattern
Nationwide in the USA
Recall initiation date
Aug 22, 2022
Initial firm notification
Letter
Center classification date
Sep 7, 2022

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-1499-2022, published Sep 14, 2022. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls